We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some encouraging evidence showing a good response to a second venetoclax treatment, from a trial of 46 CLL patients who relapsed after their initial venetoclax treatment.
The overall rate of response (ORR) to Ven2 with retreatment was 79.5% with a Complete Response (CR) of 33% after Ven1 treatment giving an ORR of 95%.
Most of the Ven1 group were relapsed/refractory CLL, so treatment naive patients should do better. The median time to progression from Ven1->Ven2 was 26 months. Median progression free survival on Ven2 was 25 months. (SD is stable disease; the CLL was not progressing.)
ashpublications.org/bloodad... (Select PDF to read the abstract.)
The abstract concludes:-
We report the largest experience of the venetoclax re-treatment strategy in patients with CLL. The results of this study have substantial clinical relevance as more patients will require treatment of CLL following time-limited venetoclax-based therapy. 14 The high ORR and durability of observed remissions support the clinical practice of venetoclax re-treatment and the development of future studies to prospectively validate venetoclax re-treatment in patients with CLL.
This is an unlocked post
Neil